Antisense Therap Ltd (ATHJF) 0.1290 $ATHJF
ATL1103 Phase II Trial - Successful Efficacy Results
PR Newswire - Tue Sep 02, 6:19PM CDT
Antisense Therapeutics Limited ("ANP" or "the Company"
is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The Phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I (sIGF-I) levels of 26% from baseline (P<0.0001) at week 14 (one week past the last dose) at the 400mg per week dose tested.
ATL1103 Acromegaly Phase II Trial Dosing Completed
PR Newswire - Tue Jul 29, 7:00AM CDT
Antisense Therapeutics Limited ("ANP" is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially life-threatening growth disorder, acromegaly has now been completed. There were no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103. Patients will continue to be monitored for a period of two months after their last dose of ATL1103.
ATL1102 for MS - Toxicology Study Main Findings
PR Newswire - Tue Apr 01, 8:45AM CDT
Antisense Therapeutics Limited ("ANP" or the "Company" is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). The Company believes that the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level.
ATL1103 Acromegaly Phase II Trial Recruitment Completed
PR Newswire - Fri Mar 21, 9:00AM CDT
Antisense Therapeutics Limited ("ANP" is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.
ATL1102 for Stem Cell Mobilisation Trial Commencement
PR Newswire - Mon Mar 17, 6:20PM CDT
Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).
Antisense Therapeutics Selected to Present at Biotech Showcase(TM) 2014
PR Newswire - Tue Jan 07, 4:49PM CST
Antisense Therapeutics Limited ("ANP" or "the Company" is pleased to advise that it has been selected to present at the Biotech Showcase 2014 conference to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA. This is a significant opportunity for ANP to present to and engage with distinguished US-based investors, prospective partners, and key industry leaders, and in particular discuss the successful progress of the company's Phase II acromegaly trial for ATL1103.
Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6d8jw/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013" report to their offering. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Scope - A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. Athersys, Inc. GlaxoSmithKline plc BioLineRx, Ltd. Celldex Therapeutics, Inc. Antisense Therapeutics Limited Actinium Pharmaceuticals, Inc. Pharmalink AB Polyphor Ltd. Kiadis Pharma B.V. Bellicum Pharmaceuticals, Inc. TaiGen Biotechnology Co., Ltd. TikoMed AB For more information visit http://www.researchandmarkets.com/research/n6...atopoietic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ANP to present at and attend major US investment, partnering and industry conferences
PR Newswire - Wed Aug 28, 6:30AM CDT
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.
Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).
ATL1103 Phase II Trial - Successful Efficacy Results
PR Newswire - Tue Sep 02, 6:19PM CDT
Antisense Therapeutics Limited ("ANP" or "the Company"
is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The Phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I (sIGF-I) levels of 26% from baseline (P<0.0001) at week 14 (one week past the last dose) at the 400mg per week dose tested. ATL1103 Acromegaly Phase II Trial Dosing Completed
PR Newswire - Tue Jul 29, 7:00AM CDT
Antisense Therapeutics Limited ("ANP"
is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially life-threatening growth disorder, acromegaly has now been completed. There were no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103. Patients will continue to be monitored for a period of two months after their last dose of ATL1103. ATL1102 for MS - Toxicology Study Main Findings
PR Newswire - Tue Apr 01, 8:45AM CDT
Antisense Therapeutics Limited ("ANP" or the "Company"
is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). The Company believes that the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level. ATL1103 Acromegaly Phase II Trial Recruitment Completed
PR Newswire - Fri Mar 21, 9:00AM CDT
Antisense Therapeutics Limited ("ANP"
is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial. ATL1102 for Stem Cell Mobilisation Trial Commencement
PR Newswire - Mon Mar 17, 6:20PM CDT
Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).
Antisense Therapeutics Selected to Present at Biotech Showcase(TM) 2014
PR Newswire - Tue Jan 07, 4:49PM CST
Antisense Therapeutics Limited ("ANP" or "the Company"
is pleased to advise that it has been selected to present at the Biotech Showcase 2014 conference to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA. This is a significant opportunity for ANP to present to and engage with distinguished US-based investors, prospective partners, and key industry leaders, and in particular discuss the successful progress of the company's Phase II acromegaly trial for ATL1103. Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6d8jw/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013" report to their offering. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Scope - A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. Athersys, Inc. GlaxoSmithKline plc BioLineRx, Ltd. Celldex Therapeutics, Inc. Antisense Therapeutics Limited Actinium Pharmaceuticals, Inc. Pharmalink AB Polyphor Ltd. Kiadis Pharma B.V. Bellicum Pharmaceuticals, Inc. TaiGen Biotechnology Co., Ltd. TikoMed AB For more information visit http://www.researchandmarkets.com/research/n6...atopoietic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ANP to present at and attend major US investment, partnering and industry conferences
PR Newswire - Wed Aug 28, 6:30AM CDT
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.
Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"
, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center). 
